Literature DB >> 15292679

Reliability of t7-based mRNA linear amplification validated by gene expression analysis of human kidney cells using cDNA microarrays.

Michael Rudnicki1, Susanne Eder, Gabriele Schratzberger, Bernd Mayer, Timothy W Meyer, Martin Tonko, Gert Mayer.   

Abstract

Genome wide gene expression analysis by cDNA microarrays is often limited by minute amounts of starting RNA. We therefore tested an optimized linear RNA amplification protocol using the RiboAmp amplification kit in the setting of cDNA microarrays. We isolated mRNA from a human kidney cell line (HK-2; ATCC) and from Universal Human Reference RNA (STR; Stratagene). After performing one and two rounds of linear RNA amplification, respectively, the amplified RNAs were co-hybridized to cDNA microarrays. Linearity and reproducibility of the individual experiments were then assessed by calculating the Pearson correlation. The intra-amplification consistency showed a correlation of 0.968 for the first round, 0.907 for the second round and 0.912 for two successive rounds of amplification. If the first round was compared to unamplified material, r was 0.925. The second round amplification yielded a correlation of 0.897 if compared to unamplified mRNA. Two rounds of amplification starting from 200 pg of mRNA compared to unamplified material resulted in a correlation of 0.868. These results indicate that linear amplification using RiboAmp kit yields amplified RNA with a high degree of linearity and reproducibility. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15292679     DOI: 10.1159/000078642

Source DB:  PubMed          Journal:  Nephron Exp Nephrol        ISSN: 1660-2129


  8 in total

1.  RNA amplification for successful gene profiling analysis.

Authors:  Ena Wang
Journal:  J Transl Med       Date:  2005-07-25       Impact factor: 5.531

2.  Limitations of mRNA amplification from small-size cell samples.

Authors:  Vigdis Nygaard; Marit Holden; Anders Løland; Mette Langaas; Ola Myklebost; Eivind Hovig
Journal:  BMC Genomics       Date:  2005-10-27       Impact factor: 3.969

3.  Gene expression signatures of morphologically normal breast tissue identify basal-like tumors.

Authors:  Greg Finak; Svetlana Sadekova; Francois Pepin; Michael Hallett; Sarkis Meterissian; Fawaz Halwani; Karim Khetani; Margarita Souleimanova; Brent Zabolotny; Atilla Omeroglu; Morag Park
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

4.  A 3-biomarker-panel predicts renal outcome in patients with proteinuric renal diseases.

Authors:  Hannes Neuwirt; Paul Perco; Alexander Kainz; Irmgard Mühlberger; Johannes Leierer; Suzie-Jane Braniff; Bernd Mayer; Gert Mayer; Michael Rudnicki
Journal:  BMC Med Genomics       Date:  2014-12-24       Impact factor: 3.063

5.  Evaluation of methods for amplification of picogram amounts of total RNA for whole genome expression profiling.

Authors:  Mathieu Clément-Ziza; David Gentien; Stanislas Lyonnet; Jean-Paul Thiery; Claude Besmond; Charles Decraene
Journal:  BMC Genomics       Date:  2009-05-26       Impact factor: 3.969

6.  Impact of sample acquisition and linear amplification on gene expression profiling of lung adenocarcinoma: laser capture micro-dissection cell-sampling versus bulk tissue-sampling.

Authors:  Eric W Klee; Sibel Erdogan; Lori Tillmans; Farhad Kosari; Zhifu Sun; Dennis A Wigle; Ping Yang; Marie C Aubry; George Vasmatzis
Journal:  BMC Med Genomics       Date:  2009-03-09       Impact factor: 3.063

Review 7.  Options available for profiling small samples: a review of sample amplification technology when combined with microarray profiling.

Authors:  Vigdis Nygaard; Eivind Hovig
Journal:  Nucleic Acids Res       Date:  2006-02-09       Impact factor: 16.971

8.  Evaluating whole transcriptome amplification for gene profiling experiments using RNA-Seq.

Authors:  Sheena L Faherty; C Ryan Campbell; Peter A Larsen; Anne D Yoder
Journal:  BMC Biotechnol       Date:  2015-07-30       Impact factor: 2.563

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.